DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
NCT ID: NCT00353574
Last Updated: 2014-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
282 participants
INTERVENTIONAL
2006-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
NCT00389675
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
NCT04475042
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Darusentan 50 mg
Darusentan 50 mg administered orally once daily
Darusentan
Darusentan capsules administered orally once daily
Darusentan 100 mg
Darusentan 100 mg administered orally once daily
Darusentan
Darusentan capsules administered orally once daily
Darusentan 300 mg
Darusentan 300 mg administered orally once daily
Darusentan
Darusentan capsules administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Darusentan
Darusentan capsules administered orally once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
Exclusion Criteria
* Treatment with another endothelin receptor antagonist within 6 months of study entry
35 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Comprehensive Heart Failure Center
Mobile, Alabama, United States
Canyon Clinical Research
Tucson, Arizona, United States
Chrishard Medical Group
Inglewood, California, United States
VA Medical Center - WLA
Los Angeles, California, United States
Sacramento Heart and Vascular
Sacramento, California, United States
Apex Research Institute
Santa Ana, California, United States
Complete Renal Care
Denver, Colorado, United States
Connecticut Clinical Research, LLC
Bridgeport, Connecticut, United States
MedStar Diabetes Institute at Washington Hospital Center
Washington D.C., District of Columbia, United States
White-Wilson Medical Center
Fort Walton Beach, Florida, United States
A.G.A. Clinical Trials
Hialeah, Florida, United States
Jacksonville Center for Clinical
Jacksonville, Florida, United States
Ricardo A. Bedoya, Cardiology
Jupiter, Florida, United States
International Research Association
Miami, Florida, United States
Cardiovascular Center of Sarasota
Sarasota, Florida, United States
Tampa Bay Nephrology Associates, PL
Tampa, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Global Research Partners
Calhoun, Georgia, United States
Kula Research
Honolulu, Hawaii, United States
Chicago Heart & Vein Clinic
Elk Grove Village, Illinois, United States
Evanston Northwestern Healthcare
Evanston, Illinois, United States
Clinical Investigation Specialists, Inc.
Gurnee, Illinois, United States
Midwest Heart Foundation
Lombard, Illinois, United States
Medical Research Institute
Slidell, Louisiana, United States
Androscoggin Cardiology Associates
Auburn, Maine, United States
Maine Research Associate
Auburn, Maine, United States
Cardiovascular Consultants of Maine
Scarborough, Maine, United States
Clinical Associates
Reisterstown, Maryland, United States
Rockville Internal Medicine Group
Rockville, Maryland, United States
Professional Clinical Research
Benzonia, Michigan, United States
Hurley Medical Center
Flint, Michigan, United States
Professional Clinical Research
Interlochen, Michigan, United States
Specialty Medical Center
Pahrump, Nevada, United States
Physicians East, PA
Greenville, North Carolina, United States
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States
COR Clinical Research
Oklahoma City, Oklahoma, United States
Southwest Cardiology Associates
Oklahoma City, Oklahoma, United States
Castlerock Clinical Research Consultants
Tulsa, Oklahoma, United States
Hillsboro Cardiology, PC
Hillsboro, Oregon, United States
Northeast Clinical Research Centers, Inc.
Allentown, Pennsylvania, United States
Heritage Cardiology Associates
Camp Hill, Pennsylvania, United States
Brandywine Clinical Research
Downingtown, Pennsylvania, United States
Green and Seidner Family Practice Associates
Lansdale, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
RI Hospital
Providence, Rhode Island, United States
Neem Research Group, Inc.
Columbia, South Carolina, United States
Internal Medicine & Industrial Medicine
DeSoto, Texas, United States
T&R Clinical, P.A.
Fort Worth, Texas, United States
Pri-Med Care
Lewisville, Texas, United States
Innovative Clinical Trials
San Antonio, Texas, United States
Burke Internal Medicine, Inc.
Burke, Virginia, United States
Manassas Clinical Research Center
Manassas, Virginia, United States
Liberty Research Center
Tacoma, Washington, United States
CIMEL
Buenos Aires, , Argentina
DIM (Clinica Privada)
Buenos Aires, , Argentina
Fundapres
Buenos Aires, , Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, , Argentina
Hospital Jose Maria Ramos Meijia
Buenos Aires, , Argentina
Hospital Municipal Bernardo Houssay
Buenos Aires, , Argentina
Medeos
Buenos Aires, , Argentina
Sanatorio Municipal
Buenos Aires, , Argentina
Centro Integrado Hospital do Rim e Hipertensao
São Paulo, , Brazil
Centro Integrado Hospital
São Paulo, , Brazil
Cambridge Cardiac Care Center
Cambridge, Ontario, Canada
Clinical Research Solutions
Kitchener, Ontario, Canada
Bispebjerg Hospital
Copenhagen, , Denmark
Hvidovre Hospital
Hvidovre, , Denmark
CIC Hopital Jeanne D'Arc
Dommartin-lès-Toul, , France
CHU de Grenoble
Grenoble, , France
Hôpital Civil, Service HTA maladies vasculaires
Strasbourg, , France
Cardiovascular Research, Karolinska Institue
Stockholm, , Sweden
University Hospital Umea
Umeå, , Sweden
Townhead Surgery
Scotland, , United Kingdom
Avenue Surgery
Wiltshire, , United Kingdom
Hathaway Medical Centre
Wiltshire, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAR-311-E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.